Denali Therapeutics (DNLI) Competitors

Qiagen (NYSE:QGEN) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Which has more volatility and risk, QGEN or DNLI?

Qiagen has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Which has preferable earnings & valuation, QGEN or DNLI?

Qiagen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.98B	4.45	$83.59M	$0.36	110.29
Denali Therapeutics	$330.53M	6.34	-$145.22M	-$2.57	-5.61

Does the media refer more to QGEN or DNLI?

In the previous week, Denali Therapeutics had 4 more articles in the media than Qiagen. MarketBeat recorded 7 mentions for Denali Therapeutics and 3 mentions for Qiagen. Denali Therapeutics' average media sentiment score of 1.43 beat Qiagen's score of 0.96 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer QGEN or DNLI?

Qiagen currently has a consensus target price of $47.71, indicating a potential upside of 20.16%. Denali Therapeutics has a consensus target price of $37.20, indicating a potential upside of 157.80%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30
Denali Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

Is QGEN or DNLI more profitable?

Qiagen has a net margin of 4.23% compared to Denali Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.92% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.23%	13.92%	8.40%
Denali Therapeutics	N/A	-32.94%	-30.04%

Does the MarketBeat Community prefer QGEN or DNLI?

Denali Therapeutics received 216 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.48% of users gave Denali Therapeutics an outperform vote while only 60.29% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 249 60.29%	Underperform Votes 164 39.71%
Denali Therapeutics	Outperform Votes 465 68.48%	Underperform Votes 214 31.52%

Do insiders & institutionals have more ownership in QGEN or DNLI?

70.0% of Qiagen shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Denali Therapeutics beats Qiagen on 11 of the 19 factors compared between the two stocks.